{"pmid":32435872,"title":"Lab-on-a-Chip Devices for Point-of-Care Medical Diagnostics.","text":["Lab-on-a-Chip Devices for Point-of-Care Medical Diagnostics.","The recent coronavirus (COVID-19) pandemic has underscored the need to move from traditional lab-centralized diagnostics to point-of-care (PoC) settings. Lab-on-a-chip (LoC) platforms facilitate the translation to PoC settings via the miniaturization, portability, integration, and automation of multiple assay functions onto a single chip. For this purpose, paper-based assays and microfluidic platforms are currently being extensively studied, and much focus is being directed towards simplifying their design while simultaneously improving multiplexing and automation capabilities. Signal amplification strategies are being applied to improve the performance of assays with respect to both sensitivity and selectivity, while smartphones are being integrated to expand the analytical power of the technology and promote its accessibility. In this chapter, we review the main technologies in the field of LoC platforms for PoC medical diagnostics and survey recent approaches for improving these assays.","Adv Biochem Eng Biotechnol","Arshavsky-Graham, Sofia","Segal, Ester","32435872"],"abstract":["The recent coronavirus (COVID-19) pandemic has underscored the need to move from traditional lab-centralized diagnostics to point-of-care (PoC) settings. Lab-on-a-chip (LoC) platforms facilitate the translation to PoC settings via the miniaturization, portability, integration, and automation of multiple assay functions onto a single chip. For this purpose, paper-based assays and microfluidic platforms are currently being extensively studied, and much focus is being directed towards simplifying their design while simultaneously improving multiplexing and automation capabilities. Signal amplification strategies are being applied to improve the performance of assays with respect to both sensitivity and selectivity, while smartphones are being integrated to expand the analytical power of the technology and promote its accessibility. In this chapter, we review the main technologies in the field of LoC platforms for PoC medical diagnostics and survey recent approaches for improving these assays."],"journal":"Adv Biochem Eng Biotechnol","authors":["Arshavsky-Graham, Sofia","Segal, Ester"],"date":"2020-05-22T11:00:00Z","year":2020,"_id":"32435872","source":"PubMed","week":"202021|May 18 - May 24","doi":"10.1007/10_2020_127","keywords":["centrifugal microfluidics","diagnostics","lab-on-a-chip","microfluidics","paper","point-of-care","smartphone"],"topics":["Diagnosis"],"weight":1,"_version_":1667521393849270272,"score":9.490897,"similar":[{"pmid":32365567,"title":"Lab-on-a-Chip Technologies for the Single Cell Level: Separation, Analysis, and Diagnostics.","text":["Lab-on-a-Chip Technologies for the Single Cell Level: Separation, Analysis, and Diagnostics.","In the last three decades, microfluidics and its applications have been on an exponential rise, including approaches to isolate rare cells and diagnose diseases on the single-cell level. The techniques mentioned herein have already had significant impacts in our lives, from in-the-field diagnosis of disease and parasitic infections, through home fertility tests, to uncovering the interactions between SARS-CoV-2 and their host cells. This review gives an overview of the field in general and the most notable developments of the last five years, in three parts: 1. What can we detect? 2. Which detection technologies are used in which setting? 3. How do these techniques work? Finally, this review discusses potentials, shortfalls, and an outlook on future developments, especially in respect to the funding landscape and the field-application of these chips.","Micromachines (Basel)","Hochstetter, Axel","32365567"],"abstract":["In the last three decades, microfluidics and its applications have been on an exponential rise, including approaches to isolate rare cells and diagnose diseases on the single-cell level. The techniques mentioned herein have already had significant impacts in our lives, from in-the-field diagnosis of disease and parasitic infections, through home fertility tests, to uncovering the interactions between SARS-CoV-2 and their host cells. This review gives an overview of the field in general and the most notable developments of the last five years, in three parts: 1. What can we detect? 2. Which detection technologies are used in which setting? 3. How do these techniques work? Finally, this review discusses potentials, shortfalls, and an outlook on future developments, especially in respect to the funding landscape and the field-application of these chips."],"journal":"Micromachines (Basel)","authors":["Hochstetter, Axel"],"date":"2020-05-06T11:00:00Z","year":2020,"_id":"32365567","source":"PubMed","week":"202019|May 04 - May 10","doi":"10.3390/mi11050468","keywords":["biomedical engineering","cancer","diagnostics","infectious diseases","microfluidics","parasites","point-of-care","single cell level"],"topics":["Diagnosis"],"weight":1,"_version_":1666138496304152576,"score":459.21686},{"pmid":32260471,"title":"In Vitro Diagnostic Assays for COVID-19: Recent Advances and Emerging Trends.","text":["In Vitro Diagnostic Assays for COVID-19: Recent Advances and Emerging Trends.","There have been tremendous advances in in vitro diagnostic (IVD) assays for coronavirus disease 2019 (COVID-19) caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). The main IVD assays used for COVID-19 employ real-time reverse transcriptase polymerase chain reaction (RT-PCR) that takes a few hours. But the assay duration has been shortened to 45 min by Cepheid. Of interest is the point-of-care (POC) molecular assay by Abbott that decreased the assay duration to just 5 min. Most molecular tests have been approved by the United States Food and Drug Administration (FDA) under emergency use authorization (EUA) and are Conformite Europeenne (CE) marked. A wide range of serology immunoassays (IAs) have also been developed that complement the molecular assays for the diagnosis of COVID-19. The most prominent IAs are automated chemiluminescent IA (CLIA), manual ELISA, and rapid lateral flow IA (LFIA), which detect the immunoglobulin M (IgM) and immunoglobulin G (IgG) produced in persons in response to SARS-CoV-2 infection. The ongoing research efforts and advances in complementary technologies will pave the way to new POC IVD assays in the coming months. However, the performance of IVD assays needs to be critically evaluated before they are employed for the clinical diagnosis of COVID-19.","Diagnostics (Basel)","Vashist, Sandeep Kumar","32260471"],"abstract":["There have been tremendous advances in in vitro diagnostic (IVD) assays for coronavirus disease 2019 (COVID-19) caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). The main IVD assays used for COVID-19 employ real-time reverse transcriptase polymerase chain reaction (RT-PCR) that takes a few hours. But the assay duration has been shortened to 45 min by Cepheid. Of interest is the point-of-care (POC) molecular assay by Abbott that decreased the assay duration to just 5 min. Most molecular tests have been approved by the United States Food and Drug Administration (FDA) under emergency use authorization (EUA) and are Conformite Europeenne (CE) marked. A wide range of serology immunoassays (IAs) have also been developed that complement the molecular assays for the diagnosis of COVID-19. The most prominent IAs are automated chemiluminescent IA (CLIA), manual ELISA, and rapid lateral flow IA (LFIA), which detect the immunoglobulin M (IgM) and immunoglobulin G (IgG) produced in persons in response to SARS-CoV-2 infection. The ongoing research efforts and advances in complementary technologies will pave the way to new POC IVD assays in the coming months. However, the performance of IVD assays needs to be critically evaluated before they are employed for the clinical diagnosis of COVID-19."],"journal":"Diagnostics (Basel)","authors":["Vashist, Sandeep Kumar"],"date":"2020-04-09T11:00:00Z","year":2020,"_id":"32260471","source":"PubMed","week":"202015|Apr 06 - Apr 12","doi":"10.3390/diagnostics10040202","keywords":["covid-19","sars-cov-2","diagnostics","immunoassays","lateral flow immunoassay (lfia)","point-of-care (poc)","real-time reverse transcriptase polymerase chain (rt-pcr)"],"locations":["Abbott"],"topics":["Diagnosis"],"weight":1,"_version_":1666138491909570561,"score":355.37155},{"pmid":32349033,"title":"Novel biosensor platforms for the detection of coronavirus infection and SARS-CoV-2.","text":["Novel biosensor platforms for the detection of coronavirus infection and SARS-CoV-2.","The recent outbreak of the SARS-CoV-2 pandemic has been causing respiratory diseases globally, damaging wide-ranges of social-economical activities. This virus is transmitted through personal contact and possibly also through ambient air. Effective biosensor platforms for the detection of this virus and the related host response are in urgent demand. These platforms can facilitate routine diagnostic assays in certified clinical labs. They can also be integrated into point-of-care products. Furthermore, environmental biosensors can be designed to detect SARS-CoV-2 in the ambient air or in the intensive care ventilators. Here, we evaluate technical components of biosensors, including the biological targets of recognition, the recognition methods and the signal amplification and transduction systems. Effective SARS-CoV-2 detectors can be designed by adequate combination of these technologies.","J Chin Med Assoc","Liang, Kung-Hao","Chang, Tai-Jay","Wang, Mong-Lien","Tsai, Ping-Hsing","Lin, Ta-Hsien","Wang, Chin-Tien","Yang, De-Ming","32349033"],"abstract":["The recent outbreak of the SARS-CoV-2 pandemic has been causing respiratory diseases globally, damaging wide-ranges of social-economical activities. This virus is transmitted through personal contact and possibly also through ambient air. Effective biosensor platforms for the detection of this virus and the related host response are in urgent demand. These platforms can facilitate routine diagnostic assays in certified clinical labs. They can also be integrated into point-of-care products. Furthermore, environmental biosensors can be designed to detect SARS-CoV-2 in the ambient air or in the intensive care ventilators. Here, we evaluate technical components of biosensors, including the biological targets of recognition, the recognition methods and the signal amplification and transduction systems. Effective SARS-CoV-2 detectors can be designed by adequate combination of these technologies."],"journal":"J Chin Med Assoc","authors":["Liang, Kung-Hao","Chang, Tai-Jay","Wang, Mong-Lien","Tsai, Ping-Hsing","Lin, Ta-Hsien","Wang, Chin-Tien","Yang, De-Ming"],"date":"2020-04-30T11:00:00Z","year":2020,"_id":"32349033","source":"PubMed","week":"202018|Apr 27 - May 03","doi":"10.1097/JCMA.0000000000000337","topics":["Diagnosis"],"weight":1,"_version_":1666138495019646976,"score":303.3284},{"pmid":32334422,"title":"Smartphone-based multiplex 30-minute nucleic acid test of live virus from nasal swab extract.","text":["Smartphone-based multiplex 30-minute nucleic acid test of live virus from nasal swab extract.","Rapid, sensitive and specific detection and reporting of infectious pathogens is important for patient management and epidemic surveillance. We demonstrated a point-of-care system integrated with a smartphone for detecting live virus from nasal swab media, using a panel of equine respiratory infectious diseases as a model system for corresponding human diseases such as COVID-19. Specific nucleic acid sequences of five pathogens were amplified by loop-mediated isothermal amplification on a microfluidic chip and detected at the end of reactions by the smartphone. Pathogen-spiked horse nasal swab samples were correctly diagnosed using our system, with a limit of detection comparable to that of the traditional lab-based test, polymerase chain reaction, with results achieved in approximately 30 minutes.","Lab Chip","Sun, Fu","Ganguli, Anurup","Nguyen, Judy","Brisbin, Ryan","Shanmugam, Krithika","Hirschberg, David L","Wheeler, Matthew B","Bashir, Rashid","Nash, David M","Cunningham, Brian T","32334422"],"abstract":["Rapid, sensitive and specific detection and reporting of infectious pathogens is important for patient management and epidemic surveillance. We demonstrated a point-of-care system integrated with a smartphone for detecting live virus from nasal swab media, using a panel of equine respiratory infectious diseases as a model system for corresponding human diseases such as COVID-19. Specific nucleic acid sequences of five pathogens were amplified by loop-mediated isothermal amplification on a microfluidic chip and detected at the end of reactions by the smartphone. Pathogen-spiked horse nasal swab samples were correctly diagnosed using our system, with a limit of detection comparable to that of the traditional lab-based test, polymerase chain reaction, with results achieved in approximately 30 minutes."],"journal":"Lab Chip","authors":["Sun, Fu","Ganguli, Anurup","Nguyen, Judy","Brisbin, Ryan","Shanmugam, Krithika","Hirschberg, David L","Wheeler, Matthew B","Bashir, Rashid","Nash, David M","Cunningham, Brian T"],"date":"2020-04-26T11:00:00Z","year":2020,"_id":"32334422","source":"PubMed","week":"202017|Apr 20 - Apr 26","doi":"10.1039/d0lc00304b","topics":["Diagnosis"],"weight":1,"_version_":1666138494050762752,"score":302.4588},{"pmid":32349121,"title":"Massively multiplexed nucleic acid detection using Cas13.","text":["Massively multiplexed nucleic acid detection using Cas13.","The overwhelming majority of globally circulating pathogens go undetected, undermining patient care and hindering outbreak preparedness and response. To enable routine surveillance and comprehensive diagnostic applications, there is a need for detection technologies that can scale to test many samples(1-3) while simultaneously testing for many pathogens(4-6). Here, we develop Combinatorial Arrayed Reactions for Multiplexed Evaluation of Nucleic acids (CARMEN), a platform for scalable, multiplexed pathogen detection. In the CARMEN platform, nanoliter droplets containing CRISPR-based nucleic acid detection reagents(7) self-organize in a microwell array(8) to pair with droplets of amplified samples, testing each sample against each CRISPR RNA (crRNA) in replicate. The combination of CARMEN and Cas13 detection (CARMEN-Cas13) enables robust testing of >4,500 crRNA-target pairs on a single array. Using CARMEN-Cas13, we developed a multiplexed assay that simultaneously differentiates all 169 human-associated viruses with >/=10 published genome sequences and rapidly incorporated an additional crRNA to detect the causative agent of the 2020 COVID-19 pandemic. CARMEN-Cas13 further enables comprehensive subtyping of influenza A strains and multiplexed identification of dozens of HIV drug-resistance mutations. CARMEN's intrinsic multiplexing and throughput capabilities make it practical to scale, as miniaturization decreases reagent cost per test >300-fold. Scalable, highly-multiplexed CRISPR-based nucleic acid detection shifts diagnostic and surveillance efforts from targeted testing of high-priority samples to comprehensive testing of large sample sets, greatly benefiting patients and public health(9-11).","Nature","Ackerman, Cheri M","Myhrvold, Cameron","Thakku, Sri Gowtham","Freije, Catherine A","Metsky, Hayden C","Yang, David K","Ye, Simon H","Boehm, Chloe K","Kosoko-Thoroddsen, Tinna-Solveig F","Kehe, Jared","Nguyen, Tien G","Carter, Amber","Kulesa, Anthony","Barnes, John R","Dugan, Vivien G","Hung, Deborah T","Blainey, Paul C","Sabeti, Pardis C","32349121"],"abstract":["The overwhelming majority of globally circulating pathogens go undetected, undermining patient care and hindering outbreak preparedness and response. To enable routine surveillance and comprehensive diagnostic applications, there is a need for detection technologies that can scale to test many samples(1-3) while simultaneously testing for many pathogens(4-6). Here, we develop Combinatorial Arrayed Reactions for Multiplexed Evaluation of Nucleic acids (CARMEN), a platform for scalable, multiplexed pathogen detection. In the CARMEN platform, nanoliter droplets containing CRISPR-based nucleic acid detection reagents(7) self-organize in a microwell array(8) to pair with droplets of amplified samples, testing each sample against each CRISPR RNA (crRNA) in replicate. The combination of CARMEN and Cas13 detection (CARMEN-Cas13) enables robust testing of >4,500 crRNA-target pairs on a single array. Using CARMEN-Cas13, we developed a multiplexed assay that simultaneously differentiates all 169 human-associated viruses with >/=10 published genome sequences and rapidly incorporated an additional crRNA to detect the causative agent of the 2020 COVID-19 pandemic. CARMEN-Cas13 further enables comprehensive subtyping of influenza A strains and multiplexed identification of dozens of HIV drug-resistance mutations. CARMEN's intrinsic multiplexing and throughput capabilities make it practical to scale, as miniaturization decreases reagent cost per test >300-fold. Scalable, highly-multiplexed CRISPR-based nucleic acid detection shifts diagnostic and surveillance efforts from targeted testing of high-priority samples to comprehensive testing of large sample sets, greatly benefiting patients and public health(9-11)."],"journal":"Nature","authors":["Ackerman, Cheri M","Myhrvold, Cameron","Thakku, Sri Gowtham","Freije, Catherine A","Metsky, Hayden C","Yang, David K","Ye, Simon H","Boehm, Chloe K","Kosoko-Thoroddsen, Tinna-Solveig F","Kehe, Jared","Nguyen, Tien G","Carter, Amber","Kulesa, Anthony","Barnes, John R","Dugan, Vivien G","Hung, Deborah T","Blainey, Paul C","Sabeti, Pardis C"],"date":"2020-04-30T11:00:00Z","year":2020,"_id":"32349121","source":"PubMed","week":"202018|Apr 27 - May 03","doi":"10.1038/s41586-020-2279-8","topics":["Diagnosis"],"weight":1,"_version_":1666138495461097472,"score":269.12366}]}